New NSAIDS study results not related to over-the-counter painkillers
Wednesday 12 January 2011, 4:23PM
410 views
The New Zealand Self Medication Industry (SMI), the industry body representing non-prescription consumer healthcare products, is aware of a study being published on BMJ.com regarding non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular safety.1
SMI executive director Tim Roper said it was important to note that the studies included in this meta-analysis, and the conclusions drawn by the study authors, are based only on the use of high, prescription doses of NSAIDs for the long term treatment of chronic conditions.
“The results of this study should not be confused with non-prescription, low doses of NSAIDs, such as ibuprofen and naproxen, which are available over-the-counter.”
Mr Roper adds that the safety profiles of over-the-counter NSAIDs are different to that of high, prescription doses. OTC ibuprofen and naproxen medicines have a long history of use as safe and effective medicines when taken as directed on the patient leaflet for the short term relief of pain and fever.
“In the interest of accuracy, it would be misleading to include any references to over-the-counter painkillers when reporting this study.”
Mr Roper says OTC medicines are safe when taken in accordance with the directions on the label. Longer term use should be managed under the care of a GP.
-ends-
1. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2010;341:c7086.
________________________________________________________________________
About SMI: The New Zealand Self-Medication Industry Association Inc (SMI) is the national trade association representing manufacturers, marketers and distributors of a wide range of products, generally available "over-the-counter" (OTC) and mainly for use in self-medication by New Zealand consumers. SMI’s mission is to promote better health through responsible self-care. This means ensuring that safe and effective self-care products are readily available to all New Zealanders at a reasonable cost. SMI works to encourage responsible use by consumers and an increasing role for cost-effective self-medication products as part of the broad national health strategy.